29 results
SD
TAK
Takeda Pharmaceutical Co
25 Apr 24
Conflict minerals disclosure
6:04am
), Baxject (III), the Flowease Infusion Set, the Dual Vial Units package, the Wide Neck DVU, Natpar mixing device, Q-Cliq Pen, Natpar Pen, Mix2Vial
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
). Since receiving the CRL Takeda worked closely with the FDA to address the Agency’s feedback; and this resubmission package included additional data … to severely active Crohn’s disease (CD) after induction therapy with ENTYVIO IV. The BLA package is based on data from VISIBLE 2 trial that assessed
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
Letter (CRL). Since receiving the CRL Takeda worked closely with the FDA to address the Agency’s feedback; and this resubmission package included … with moderately to severely active Crohn’s disease (CD) after induction therapy with ENTYVIO IV. The BLA package is based on data from VISIBLE 2 trial
6-K
TAK
Takeda Pharmaceutical Co
1 Aug 23
Current report (foreign)
6:10am
; this resubmission package includes additional data collected to investigate the use of subcutaneous administration of Entyvio. The contents of the letter were
6-K
EX-99.1
amyw45pe7ef
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
e84qwe7
30 May 23
Current report (foreign)
6:11am
SD
t8m o0jklo5owq
15 May 23
Conflict minerals disclosure
6:09am
6-K
EX-99.1
rj5ant 5ts9cwkmi5q8
31 May 22
Current report (foreign)
6:07am
SD
fapbeof
13 May 22
Conflict minerals disclosure
6:10am
6-K
5vxie5
10 Feb 22
Current report (foreign)
6:03am
6-K
5am26ka4bh
5 Nov 21
Current report (foreign)
6:02am
6-K
25grwjv8o
6 Aug 21
Current report (foreign)
6:06am
SD
zxox8e
17 May 21
Conflict minerals disclosure
6:21am
F-3ASR
EX-1.1
kf0qwc9sptcr z2gbe
24 Jun 20
Automatic shelf registration (foreign)
4:30pm
424B3
dsi0a a8o62lhb
14 Nov 19
Prospectus supplement
6:10am
F-4/A
ieor9u9 d15l
12 Nov 19
Registration of securities (foreign) (amended)
9:50am